Stipulation between the Debtors, Equity Committee and PAR Pharma includes the following provisions:
• The PAR claim will be heard by an arbitration panel;
• The PAR claim will be limited to a max possible recovery of $3.5 million, which is down from the $11.625 million they originally claimed to be entitled to; and
• Unless agreed otherwise, the arbitration hearing must be concluded by January 31, 2011 but the panel’s decision is not required to be rendered by this date.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.